Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: inada h. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: inada h. Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568. Cancers (Basel). 2023. PMID: 36900359 Free PMC article.
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Yoshimaru Y, Nagaoka K, Tanaka K, Narahara S, Inada H, Kurano S, Tokunaga T, Iio E, Watanabe T, Setoyama H, Tateyama M, Yoshida K, Tsunoda T, Nakamura Y, Tanaka M, Sasaki Y, Tanaka Y. Yoshimaru Y, et al. Among authors: inada h. Hepatol Res. 2024 May;54(5):451-464. doi: 10.1111/hepr.13995. Epub 2023 Dec 27. Hepatol Res. 2024. PMID: 38018304
Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.
Sugimoto R, Inada H, Tanaka Y, Senju T, Aratake Y, Nakanishi A, Miki M, Lee L, Hisano T, Matsumoto Y, Mano Y, Iguchi T, Sugimachi K, Okumura Y, Taguchi K, Furukawa M. Sugimoto R, et al. Among authors: inada h. Clin J Gastroenterol. 2021 Oct;14(5):1484-1490. doi: 10.1007/s12328-021-01470-y. Epub 2021 Jun 27. Clin J Gastroenterol. 2021. PMID: 34176067 Free PMC article.
Risk factors for de novo hepatitis B during solid cancer treatment.
Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Sugimoto R, et al. Among authors: inada h. World J Clin Cases. 2020 Dec 26;8(24):6264-6273. doi: 10.12998/wjcc.v8.i24.6264. World J Clin Cases. 2020. PMID: 33392307 Free PMC article.
Surface sensitivity of atomic resolution secondary electron imaging.
Saitoh K, Oyobe T, Igarashi K, Sato T, Matsumoto H, Inada H, Endo T, Miyata Y, Usami R, Takenobu T. Saitoh K, et al. Among authors: inada h. Microscopy (Oxf). 2024 Sep 20:dfae041. doi: 10.1093/jmicro/dfae041. Online ahead of print. Microscopy (Oxf). 2024. PMID: 39300960
436 results